Cytodyn OTC Stock Insiders


USD 0.35  0.01  2.78%   

Cytodyn employes about 23 people. The company is managed by 21 executives with total tenure of roughly 102 years, averaging almost 4.0 years of service per executive having 1.1 employees per reported executive. Break down of Cytodyn management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Cytodyn future performance.
Continue to Trending Equities.
  Nader Pourhassan  CEO
CEO and President and Director
  Denis Burger  Chairman
Vice Chairman and Chief Science Officer
  Scott Kelly  Chairman
Chairman of the Board

Cytodyn Management Team Effectiveness

Cytodyn has return on total asset (ROA) of (1.2511) % which means that it has lost $1.2511 on every $100 spent on asset. This is way below average. Cytodyn management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Cytodyn Workforce Comparison

Cytodyn is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 19,402. Cytodyn adds roughly 23.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Cytodyn Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytodyn insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytodyn's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cytodyn insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cytodyn Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Highest value over a specified period line plots max value of Cytodyn price series.

Cytodyn Notable Stakeholders

A Cytodyn stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytodyn often face trade-offs trying to please all of them. Cytodyn's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytodyn's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nader Pourhassan - CEO and President and DirectorProfile
Denis Burger - Vice Chairman and Chief Science OfficerProfile
Scott Kelly - Chairman of the BoardProfile
Richard Pestell - Vice Chairman of the Board and Chief Medical OfficerProfile
Anthony Caracciolo - Chairman of the BoardProfile
Michael Mulholland - CFO, Treasurer, Corporate SecretaryProfile
Nitya Ray - CTO and Head of Process Sciences, Manufacturing & Supply ChainProfile
Carl Dockery - DirectorProfile
Bruce Montgomery - Independent DirectorProfile
David Welch - DirectorProfile
Jordan Naydenov - Independent DirectorProfile
Gregory Gould - Independent DirectorProfile
Michael Klump - Independent DirectorProfile
Marek Ciszewski - Managing DirectorProfile
Robert Schatz - Managing DirectorProfile
Bernie PMP - VP OperationsProfile
Antonio CPA - Treasurer CFOProfile
Cyrus MBA - PresidentProfile
George Bitar - Head DirectorProfile
Kush Dhody - VP OperationsProfile
Cristina Leon - InvestorsProfile

About Cytodyn Management Performance

The success or failure of an entity such as Cytodyn often depends on how effective the management is. Cytodyn management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytodyn management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytodyn management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.
The data published in Cytodyn's official financial statements usually reflect Cytodyn's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cytodyn. For example, before you start analyzing numbers published by Cytodyn accountants, it's critical to develop an understanding of what Cytodyn's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Cytodyn's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytodyn's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cytodyn's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cytodyn. Please utilize our Beneish M Score to check the likelihood of Cytodyn's management to manipulate its earnings.

Cytodyn Workforce Analysis

Traditionally, organizations such as Cytodyn use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytodyn within its industry.

Cytodyn Manpower Efficiency

Return on Cytodyn Manpower

Revenue Per Employee11.6 K
Revenue Per Executive12.7 K
Net Loss Per Employee9.2 M
Net Loss Per Executive10 M
Continue to Trending Equities. Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Cytodyn OTC Stock analysis

When running Cytodyn price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Please note, there is a significant difference between Cytodyn's value and its price as these two are different measures arrived at by different means. Investors typically determine Cytodyn value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytodyn's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.